3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Leukemia, Myeloid, Acute
4
Squamous Cell Carcinoma of Head and Neck
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Sezary Syndrome
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Myeloid Malignancies
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Hematologic Neoplasms
1
Interventions
Nivolumab
4
pertuzumab
2
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Docetaxel
2
Capecitabine
2
ulocuplumab
1
tremelimumab
1
tazarotene
1
talazoparib
1
romiplostim
1
pexidartinib
1
pamiparib
1
onartuzumab
1
magrolimab
1
entrectinib
1
cobimetinib
1
atezolizumab
1
Sunitinib
1
Rifampin
1
Ramucirumab
1
Radiosurgery
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
Midazolam
1
MK-4166
1
LY3022855
1
LY2510924
1
LY-2157299
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Solid Tumor
×
magrolimab
×
Clear all
NCT04827576
2025-05-08
ELEVATELung&UC
Gilead Sciences
Phase 2
Terminated
106 enrolled
22 charts